{"transactions":[{"id":735051,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":361578,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are owned directly by BKJLAGG, LLC (\"BKJLAGG\") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium."}],"balance_after":834489,"derivative":{"underlying":"common stock, $0.01 par value per share","underlying_shares":361578},"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735050,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":238422,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are owned directly by Domicilium Real Estate Fund III LP (the \"Fund\") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":0,"derivative":{"underlying":"common stock, $0.01 par value per share","underlying_shares":238422},"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735049,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock, $0.01 par value per share","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":361578,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The securities are owned directly by BKJLAGG, LLC (\"BKJLAGG\") and may be deemed to be indirectly beneficially owned by (i) Domicilium, the investment adviser to BKJLAGG, and (ii) Daniel Simon, the managing member of Domicilium."}],"balance_after":361578,"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":735048,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"common stock, $0.01 par value per share","published_at":"2026-06-17T21:15:00.000Z","date":"2026-06-10","kind":"other","planned":false,"acquired":true,"shares":238422,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each pre-funded warrant to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\") was exchanged (pursuant to the terms of the Pre-Funded Warrant) for 1 share of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are owned directly by Domicilium Real Estate Fund III LP (the \"Fund\") and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\"), the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (ii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":238422,"source":{"system":"sec-edgar","filing":"0000919574-26-004021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426004021/ownership.xml","form_type":"4"}},{"id":748687,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-funded Warrant","published_at":"2026-06-05T14:44:56.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":true,"shares":113636,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\"), Domicilium Real Estate Fund III LP (the \"Fund\"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. A holder of Pre-Funded Warrants may not exercise the Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of common stock outstanding immediately after giving effect to such exercise."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":238422,"derivative":{"underlying":"Common Stock, $0.01 par value per share","underlying_shares":113636},"source":{"system":"sec-edgar","filing":"0000919574-26-003845","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426003845/ownership.xml","form_type":"4"}},{"id":748686,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":37447,"kind":"organization","name":"Domicilium Real Estate Fund III LP","position":1,"cik":"0001945896","reported_name":"Domicilium Real Estate Fund III LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, $0.01 par value per share","published_at":"2026-06-05T14:44:56.000Z","date":"2026-05-27","kind":"other","planned":false,"acquired":false,"shares":113636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the pre-funded warrants to purchase shares of the Issuer's common stock (the \"Pre-Funded Warrants\"), Domicilium Real Estate Fund III LP (the \"Fund\"), exchanged 1,250,000 shares of common stock of the Issuer for pre-funded warrants to purchase an equivalent number of shares of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"These securities reflect a 11 for 1 reverse stock split effective May 29, 2026."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The securities are owned directly by the Fund and may be deemed to be indirectly beneficially owned by (i) Domicilium Capital Partners LLC, (\"Domicilium\") the investment adviser to the Fund, (ii) Domicilium Real Estate Fund III GP LLC (the \"General Partner\"), the general partner of the Fund, and (iii) Daniel Simon, the managing member of Domicilium and the General Partner."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000919574-26-003845","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1945896/000091957426003845/ownership.xml","form_type":"4"}}]}